# A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML

> **NCT02896842** · PHASE2 · COMPLETED · sponsor: **Versailles Hospital** · enrollment: 139 (actual)

## Conditions studied

- Leukemia, Myelogenous, Chronic, BCR-ABL Positive

## Interventions

- **DRUG:** Posology dose modification
- **OTHER:** active comparator

## Key facts

- **NCT ID:** NCT02896842
- **Lead sponsor:** Versailles Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2015-03
- **Final completion:** 2016-12
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2017-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896842, "A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02896842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*